Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pagel

Showing results (101-110 of 245) with videos related to

Pageof 25
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapyAjay K Gopal, John M Pagel, Joseph G Rajendran, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2005
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemiaDaniella M B Kerbauy, Faith Chyou, Ted Gooley, et al.
Bioconjugate Chemistry|September 8, 2009
Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatineD Scott Wilbur, Monica S Thakar, Donald K Hamlin, et al.
American Journal of Hematology|October 18, 2019
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphomaAlex F Herrera, Andre Goy, Amitkumar Mehta, et al.
Advances in Therapy|October 12, 2020
Baseline Demographics and Clinical Characteristics Among 3471 US Patients Hospitalized with COVID-19 and Pulmonary Involvement: A Retrospective StudyJennie H Best, Shalini V Mohan, Amanda M Kong, et al.
Leukemia & Lymphoma|May 3, 2008
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaBrian G Till, Theodore A Gooley, Nathan Crawford, et al.
Cancer Research|June 19, 2007
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomasJohn M Pagel, Anastasia Pantelias, Nathan Hedin, et al.
British Journal of Haematology|August 23, 2014
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patientsJohn M Pagel, Stephen E Spurgeon, John C Byrd, et al.
Women'S Health Reports (New Rochelle, N.Y.)|February 26, 2024
Reflect, Inspire, Strengthen, and Empower 2.0 Program: Advancing Careers and Leadership for Women Physician Staff in an Academic InstitutionJi Yun Kang, Ivana T Croghan, Caroline L Matchett, et al.
Blood|January 7, 2009
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsJohn M Pagel, Nural Orgun, Donald K Hamlin, et al.
Pageof 25

Showing results (101-110 of 245) with videos related to

Sort By:
Pageof 25
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapyAjay K Gopal, John M Pagel, Joseph G Rajendran, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2005
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemiaDaniella M B Kerbauy, Faith Chyou, Ted Gooley, et al.
Bioconjugate Chemistry|September 8, 2009
Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatineD Scott Wilbur, Monica S Thakar, Donald K Hamlin, et al.
American Journal of Hematology|October 18, 2019
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphomaAlex F Herrera, Andre Goy, Amitkumar Mehta, et al.
Advances in Therapy|October 12, 2020
Baseline Demographics and Clinical Characteristics Among 3471 US Patients Hospitalized with COVID-19 and Pulmonary Involvement: A Retrospective StudyJennie H Best, Shalini V Mohan, Amanda M Kong, et al.
Leukemia & Lymphoma|May 3, 2008
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaBrian G Till, Theodore A Gooley, Nathan Crawford, et al.
Cancer Research|June 19, 2007
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomasJohn M Pagel, Anastasia Pantelias, Nathan Hedin, et al.
British Journal of Haematology|August 23, 2014
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patientsJohn M Pagel, Stephen E Spurgeon, John C Byrd, et al.
Women'S Health Reports (New Rochelle, N.Y.)|February 26, 2024
Reflect, Inspire, Strengthen, and Empower 2.0 Program: Advancing Careers and Leadership for Women Physician Staff in an Academic InstitutionJi Yun Kang, Ivana T Croghan, Caroline L Matchett, et al.
Blood|January 7, 2009
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsJohn M Pagel, Nural Orgun, Donald K Hamlin, et al.
Pageof 25